ClinicalTrials.gg

Program

idelalisib

Also written as “Idelalisib”, “CAL-101” and “CAL101”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Follicular · Idiopathic Pulmonary Fibrosis · Primary Myelofibrosis · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.

Furthest: phase 4, since Apr 12, 201628 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences260 open or runningphase 4since Apr 12, 2016Jul 1, 2008none ahead
Calluna Pharma AS11 open or runningphase 2since Dec 16, 2024Dec 16, 2024Nov 2026phase 2 · NCT06736990
Eli Lilly11 open or runningphase 4since Oct 16, 2025Oct 16, 2025May 2030phase 4 · NCT07218341

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Jul 1, 2008.

  1. Nov 14, 20122 phase 3 studies in Lymphoma, FollicularGilead Sciences · NCT01732926, NCT01732913
  2. Feb 19, 2013Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT01796470 · 66 enrolled · United States
  3. Nov 5, 20132 phase 3 studies in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT01980888, NCT01980875
  4. Jan 22, 2014Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT02044822 · 102 enrolled · United States, Australia, Austria and more
  5. Sep 13, 2014Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT02242045 · 6 enrolled · Japan
  6. Oct 3, 2014Phase 2 study in Lymphoma, FollicularGilead Sciences · NCT02258529 · 10 enrolled · United States
  7. May 1, 2015Phase 1 study in Primary MyelofibrosisGilead Sciences · NCT02436135 · 10 enrolled · United States
  8. Jun 8, 2015Phase 1 study in RecurrenceGilead Sciences · NCT02468557 · 16 enrolled · United States
  9. Aug 27, 2015Phase 3 study in Lymphoma, FollicularGilead Sciences · NCT02536300 · 96 enrolled · Australia, Canada, Czechia and more
  10. Apr 12, 2016Phase 4 study in Lymphoid MalignanciesGilead Sciences · NCT02739360 · 3 enrolled · Netherlands
  11. Nov 16, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT02968563 · 35 enrolled · Germany
  12. Nov 17, 2017Phase 1 study in Lymphoma, Large B-Cell, DiffuseGilead Sciences · NCT03349346 · France, Italy, Poland and more
  13. Dec 16, 2024Calluna Pharma AS's first study: phase 2 study in Idiopathic Pulmonary FibrosisNew to Calluna Pharma ASCalluna Pharma AS · NCT06736990 · 150 enrolled · United States, Denmark, France and more
  14. Oct 16, 2025Eli Lilly's first study: phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellNew to Eli LillyEli Lilly · NCT07218341 · 150 planned · United States, Australia, Austria and more

Ahead

  1. Nov 2026Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisCalluna Pharma AS · NCT06736990
  2. May 2030Primary completion: phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT07218341

TargetBeta

PIK3CD →read by rule
“An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) ”NCIt, by rule
“PI3-kinase p110-delta subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CD

ProgramCompanyFurthest phaseStudies
duvelisibruleSecuraBiophase 326
leniolisibrulePharming Groupphase 39
gedatolisibrulePfizerphase 39
paxalisibrulekazia-therapeutics-limitedphase 24
roginolisibruleioncturaphase 24

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07218341Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more4RecruitingEli LillyMay 2030150
NCT06736990Idiopathic Pulmonary Fibrosis · United States, Denmark, France and more2Active, not recruitingCalluna Pharma ASNov 2026150
NCT03349346Lymphoma, Large B-Cell, Diffuse · France, Italy, Poland and more1WithdrawnGilead SciencesFeb 20210
NCT02968563Leukemia, Lymphocytic, Chronic, B-Cell · Germany2CompletedGilead SciencesJun 17, 201935
NCT02739360Lymphoid Malignancies · Netherlands4TerminatedGilead SciencesDec 28, 20173
NCT02536300Lymphoma, Follicular · Australia, Canada, Czechia and more3TerminatedGilead SciencesSep 27, 202296
NCT02468557Recurrence · United States1TerminatedGilead SciencesApr 27, 201616
NCT02436135Primary Myelofibrosis · United States1TerminatedGilead SciencesNov 20, 201710
NCT02258529Lymphoma, Follicular · United States2TerminatedGilead SciencesApr 12, 201610
NCT02242045Leukemia, Lymphocytic, Chronic, B-Cell · Japan1CompletedGilead SciencesDec 25, 20146
NCT02044822Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more2TerminatedGilead SciencesApr 27, 2016102
NCT01980888Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3TerminatedGilead SciencesMay 30, 2016311
NCT01980875Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3TerminatedGilead SciencesMay 13, 201657
NCT01796470Leukemia, Lymphocytic, Chronic, B-Cell · United States2TerminatedGilead SciencesJan 201566
NCT01732926Lymphoma, Follicular · United States, Australia, Canada and more3TerminatedGilead SciencesMay 17, 2016475
NCT01732913Lymphoma, Follicular · United States, Australia, Czechia and more3TerminatedGilead SciencesMay 18, 2016295
NCT01659047Leukemia, Lymphocytic, Chronic, B-Cell2WithdrawnGilead SciencesDec 20140
NCT01659021Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3TerminatedGilead SciencesAug 15, 2018261
NCT01569295Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3CompletedGilead SciencesJun 10, 2019416
NCT01539512Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany and more3CompletedGilead SciencesOct 2013220
NCT01539291Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany and more3TerminatedGilead SciencesMay 21, 2018161
NCT01393106Hodgkin Disease · United States2CompletedGilead SciencesAug 201425
NCT01306643Lymphoma, Follicular · United States2CompletedGilead SciencesAug 201518
NCT01282424Lymphoma, Follicular · United States, France, Germany and more2CompletedGilead SciencesMay 2, 2018125
NCT01203930Leukemia, Lymphocytic, Chronic, B-Cell · United States2TerminatedGilead SciencesAug 2015105
NCT01090414Leukemia, Lymphocytic, Chronic, B-Cell · United States2TerminatedGilead SciencesJun 18, 2018202
NCT00836914Rhinitis, Allergic · Austria1CompletedGilead SciencesMar 200941
NCT00710528Leukemia, Lymphocytic, Chronic, B-Cell · United States1CompletedGilead SciencesDec 2011192

How it is read

Names in the registry

  • “Idelalisib”, 24 entries
  • “CAL-101”, 2 entries
  • “CAL101”, 1 entry
  • “GS-1101”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.